Date & Time
This program is the second in a series of 2013-2014 programs with a focus on cancer, particularly as seen through the lens of Siddhartha Mukherjee’s book The Emperor of All Maladies.
Breakthroughs in genomics and targeted therapies have now reached the clinic, and will revolutionize the practice of oncology. However, in order to change outcomes in cancer, we can no longer use old paradigms for treating patients and designing clinical trials. In effect, genomics is a disruptive technology because it has unveiled a reality for cancer that makes standard operating procedures obsolete. Yet we continue to retrofit traditional treatments into this new reality. This can and must change if we are to transform the lives of patients with cancer.
To view a recording of this event, please click here.
Dr. Razelle Kurzrock joined UC San Diego Moores Cancer Center in November 2012 as Senior Deputy Center Director for Clinical Science and Murray Professor of Medicine. Her charge is broad, including growing and innovating the clinical trials program, and directing the Clinical Trials Office as well as the newly established Center for Personalized Therapy.
Dr. Kurzrock is best known for successfully creating the largest Phase I clinical trials department in the world while at the University of Texas M.D. Anderson Cancer Center. She was the Chair of the department designated Investigational Cancer Therapeutics from its inception until August 2012 when she moved to UC San Diego Moores Cancer Center. In FY12 alone, this department enrolled about 1,200 patients in 128 therapeutic trials. Dr. Kurzrock’s unique approach emphasized using cutting-edge molecular profiling technologies to match patients with novel targeted therapies reflecting a personalized strategy to optimize cancer treatment.
Dr. Charles Redfern is a graduate of U.C. Berkeley, Johns Hopkins Medical School, and the Medical Oncology Training Program at U.C. San Francisco. Dr. Redfern joined Oncology Associates of San Diego in 1999. He became Director of the Oncology Advisory Board at Sharp Memorial Hospital in 2003 and Co-Director of Oncology Services in 2013.
Dr. Redfern has a busy community-based practice and mostly sees patients with gastrointestinal malignancies and prostate cancer. He has helped manage oncology clinical trials for Sharp Healthcare for nearly 15 years. Some of the clinical studies he has been involved with include FavId, Provenge, Zytiga, and Xtandi. Currently, he helps manage newer immunotherapy studies such as PD-L1 antibody therapy and Cabozantinib in prostate cancer.